miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.

Y, Wang; R, Lieberman; J, Pan; Q, Zhang; M, Du; P, Zhang; M, Nevalainen; M, Kohli; NK, Shenoy; H, Meng; M, You; L, Wang

doi:10.1186/s12943-016-0556-9

Public

miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.

Shared by NobleBlocks on Nov 10, 2016 • 12:00 AM UTC

Authors:

Wang Y

Lieberman R

Pan J

Abstract

<h4>Background</h4>Treatment options for metastatic castrate-resistant prostate cancer (mCRPC) are limited and typically are centered on docetaxel-based chemotherapy. We previously reported that elevated miR-375 levels were significantly associated with poor overall survival of mCRPC patients. In th...

Subject

prostate cancer

Mir-375

Docetaxel Resistance

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!